Real-world study of efgartigimod for CIDP
Treatments studied
Part of Brain & nervous system, Immune system & allergy clinical trials.
This study looks at how well efgartigimod works in everyday use for people with chronic inflammatory demyelinating polyneuropathy (CIDP). It aims to understand the real-world benefits of this treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older
- You have been diagnosed with chronic inflammatory demyelinating polyneuropathy (CIDP)
- Your doctor plans to start you on efgartigimod as part of your CIDP treatment
- You have never taken efgartigimod before
- You do not have polyradiculoneuropathy caused by another condition
- You are not currently in another clinical trial or planning to join one before starting efgartigimod
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This program provides early access to an investigational medication called efgartigimod for adults with CIDP who haven't responded well to usual treatments. The drug aims to reduce the immune attack on nerves and may help manage symptoms when other options fail.
This study tests an investigational drug called empasiprubart against standard IVIg in adults with CIDP. The goal is to see if it is safer and more effective for people who still have symptoms despite IVIg therapy.
This Phase 1 study compares IVIG given through an IV versus SCIG given under the skin, for people with CIDP. It aims to find the right weekly SCIG dose based on your current IVIG dose, which could make treatment more convenient.
This study tests a new medicine called Empasiprubart for adults with ongoing CIDP. It aims to see if fewer symptoms return and if it can replace current treatments.
This study looks at how well current treatments work for people with CIDP (a nerve condition causing weakness). It tracks symptoms and daily function over time to help doctors understand which treatments may work best.
This study tests a new intravenous immunoglobulin (IVIG) treatment called KIg10 (QIVIGY) for people with chronic inflammatory demyelinating polyneuropathy (CIDP). It aims to see if this treatment can help manage symptoms and maintain stability.
Hear when a new Chronic Inflammatory Demyelinating Polyradiculoneuropathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.